

FIG. 21


CAGTGTGCTG GCGGCCCGGC GCGAGCCGGC CCGGCCCCGG TCGGGCCTCC -26 ATG AAC TTT CTG CTG TCT TGG GTG CAT TGG AGC F L L S W V H -20 CTC GCC TTG CTG CTC TAC CTC CAC CAT GCC AAG TGG TCC CAG -15 L L Y L H H A K -10 GCT GCA CCC ATG CCA GAA GGA GGG GGG CAG AAT CAT CAC E Α G G G Q N +5 +10 171 GAA GTG GTG AAG TTC ATG GAT GTC TAT CAG CGC AGC TAC TGC 13 V V K F M D V Y Q R Y +20 +25 CAT CCA ATC GAG ACC CTG GTG GAC ATC TTC CAG GAG TAC Ι E T V D I L F Q E +30 +35 CCT GAT GAG ATC GAG TAC ATC TTC AAG CCA TCC TGT GTG CCC P . . D E I E Y I F K P S C V +40 +45 CTG ATG CGA TGC GGG GGC TGC TGC AAT GAC GAG GGC CTG R C G G C C N D E G M +55 +60 +65 333 GAG TGT GTG CCC ACT GAG GAG TCC AAC ATC ACC ATG CAG ATT 67 V P T E E S N I Τ Ι +70 +75 +80 ATG CGG ATC AAA CCT CAC CAA GGC CAG CAC ATA GGA GAG Ι K P H Q G Q H I +85 ATG AGC TTC CTA CAG CAC AAC AAA TGT GAA TGC AGA CCA AAG 414 94 S F L Q H N K C E С R +95 +100 +105 AAA GAT AGA GCA AGA CAA GAA AAT CCC TGT GGG CCT TGC R Q E N D R Α P С P +110 +120 +115 TCA GAG CGG AGA AAG CAT TTG TTT GTA CAA GAT CCG CAG ACG 121 R R K H L F V Q D +125 +130 TGT AAA TGT TCC TGC AAA AAC ACA GAC TCG CGT TGC AAG C S C K N T D S R C +135 +140 +145

FIG. 1A


576 148			GAG TT. E L	A AAC GA N E +155	R		TGC C	R	TGT C 160	GAC D
	AAG CCG K P	AGG CGG R R +165	TGA GC	CGGGCA G	GAGGA	AGGA	GCC	гссст	CA	
661	GGGTTTCG	GG AACC	AGATCT (CTCACCAG	GA AA	GACTO	GATA	CAGA	ACGA	ATC
	GATACAGA	AA CCAC	GCTGCC (GCCACCAC	AC CA	TCAC	CATC	GACA	GAAC	CAG
761	TCCTTAAT	CC AGAA	ACCTGA	ATGAAGG	AA GA	GGAGA	ACTC	TGC	CAGA	AGC
	ACTTTGGG	TC CGGA	GGGCGA (GACTCCGG	CG GA	AGCAI	TCC	CGGG	CGGC	GTG
861	ACCCAGCA	CG GTCC	CTCTTG (GAATTGGA	TT CG	CCATI	ATT	TTTT	TCTI	GC
	TGCTAAAT	CA CCGA	GCCCGG A	AGATTAG	AG AG	TTTT#	TTT	CTGG	GATI	CC
961	TGTAGACA	CA CCGC	GCCGC (CAGCACAC	TG					

TGTAGACACA CCGCGGCCGC CAGCACACTG

Plasmin releases the heparinbinding domains of VEGF165



VEGF displays separate and distinct receptor binding sites for KDR and FLT



KDR receptor binding is mediated by the (1-110) dimer of VEGF




FIG. 4

Charged-to-Alanine Scan Mutations in VEGF

<u> Foci</u>	<u>Mutation</u>	Loci	Mustation
5	E5A		<u>Mutation</u>
12	H11A, H12A, E13A	64	E64A
17.5	K16A, D19 T	64.7	D63A, E64A, E67A
23	DOWN DIST	67	E67A
27	R23A	72.5	E72A, E73A
	H27A	82	R82A
28.5	H27A, E30A	84	K84A
30	E30A	84	
34	D34A	86	R82A, K84A, H86A
36	D34A, E38A		H86A
38	E38A	91.5	H90A, E93A
41	D41A	100	H99A, K101A
42	· · ·	103	E103A
	E42A	105	R105A
42.3	D41A, E42A, E44A	107.5	K107A, K108A
44	E44A	108.5	VÝDD(107 110)
48	K48A	109.5	KKDR(107-110)AAAA
56	R56A		D109A, R110A
63	D63A	113	R112A, E114A
	20071		

KDR Binding is primarily mediated by R82, K84, H86




FIG. 6

FLT-1 Binding is mediated by D63, E64, E67




FIG. 7

Extra-glycosylation at 82 blocks KDR binding




FIG. 8

Mutations in 82-86 site block KDR binding




FIG. 9A

Mutations in 63-67 site block FLT binding






FIG. 9B

Multiple mutations have synergistic effect with KDR: K84A is a potent single alanine substitution



VEGF Mutants with Decreased KDR Receptor Binding are Weak Endothelial Cell Mitogens



R82 K84 H86




FIGURE 13




FIG. 14

Augarore Electrophoreris

Hind 111 SDVF165 ı. ECORI Hind 111 Hind in ligation of insert into cut pars with Ty ligase isolated competent ds DNA Qiegen-kit PRKS isolated 4. ss DNA template by extraction 5. mutajanic in vitro site directed ds DNA mutageners SS DNA template 6. ds DNA orguencing human hid ray - Jales 7. Final expression system

FIG. 15

KBR-IgG Binding of VEGF Variants

no-heparin-

.J

FIG. 16

. . .

THE THE STREET OF STREET

IC 50 (NG/ML)




FIG. 17





FIG. 18



Polyclonal-Monoclonal ELISA (ng/ml)

FIG. 20